The share price of medical supplies titan Medline rose by 40% during Wednesday's trading on the first day of its initial public offering.

AI has been the buzzword on Wall Street for nearly all of 2025, but Medline's IPO is catching the eye of investors.

Shares in Andersen, which acquired the rights to the name in 2014, closed 47 per cent higher at $23.50, compared to their IPO price of $16, giving it a fully diluted market capitalisation of about $2.6bn.

It priced the offering at $29 a share. In its prospectus, the company said it has experienced more than 50 years of consecutive annual sales growth, culminating in sales north of $20 billion every year since 2021. Medline was also the biggest IPO of the year. The company raised $6.26 billion.

Phytochem Remedies IPO allotment will be finalised on December 23, while the listing date for its shares is December 26. Shares of the company are slated to debut on the BSE SME.

A bid by individual investors to grab a sliver of SpaceX before it goes public has propelled a niche ETF into the spotlight, highlighting retail euphoria over Elon Musk’s business empire and the scramble for private-company exposure.

SpaceX has authorized an insider share sale that values Elon Musk's rocket and satellite maker at about $800 billion, according to a company message seen by Bloomberg on Dec. 12.

Elon Musk's SpaceX is eyeing an initial public offering that could be the largest ever, at least partially driven by a plan to launch AI data centers into orbit.

MetaX Integrated Circuits Shanghai Co. soared in its first day of trading on Wednesday, the latest outsized debut by a Chinese chipmaker after similar gains by Moore Threads Technology Co. earlier this month.